Background: Mismatched unrelated donor (MMURD) transplantation is widely used in patients who lack a matched unrelated donor (MUD). Despite several published observational studies, the magnitude of risk associated with 9 out of 10 MMURD transplant and that of HLA-specific mismatches is still unclear. We performed a meta-analysis to assess the difference in outcomes of MUD to those of MMURD transplant.
Methods: A comprehensive search of Medline and EMBASE was performed through April 2014. We included published manuscripts that reported outcomes of adult patients with hematologic malignancies who underwent MUD (matched at HLA-A, B, C and DRB1 at a minimum) or MMURD transplant (single antigen or allele mismatch only). The pooled relative risks (RR) from hazard ratios and risk ratios and 95% confidence intervals (CI) were estimated using a DerSimonian-Laird random-effects model. Heterogeneity was tested using the I2 statistic and Cochran Q test, and sources of heterogeneity were evaluated using univariate meta-regression. Statistical analyses were performed using Stata v13.1.
Results: Twenty-two studies were included, representing 38,877 transplants. Nine out of 10 MMURD transplant was associated with a higher risk of overall mortality compared with 10 out of 10 MUD transplant (n=10; RR 1.32, 95% CI 1.17–1.49). No significant sources of heterogeneity were identified. MMURD transplant was associated with worse disease-free survival compared with MUD transplant (n=6; RR 1.20, 95% CI, 1.08–1.33). The pooled effect estimates for grade II-IV acute and chronic GVHD were 1.23 (n=4; 95% CI 0.99–1.53) and 1.08 (n=3; 95% CI 0.76–1.54) respectively. Single antigen/allele mismatches at HLA-A, B, C or DRB1 were associated with a higher risk of grade III-IV acute GVHD and overall mortality, but not chronic GVHD as compared with MUD transplant (Table). Disease-free survival was only worse for HLA-B mismatch.
Conclusion: MMURD transplant is associated with significantly higher risk of overall mortality and acute GVHD, but not chronic GVHD compared with MUD transplant. This risk is associated with HLA-A, -B, -C, and –DRB1, but not -DQB1 and -DPB1 mismatches.
Pooled RR (95% CI)
| Grade II-IV Acute GVHD
| Grade III-IV Acute GVHD
| Chronic GVHD
| Disease-Free Survival
| Overall Survival
|
HLA-A
| 1.12 (0.75 - 1.66)
| 1.57 (1.29 - 1.90)
| 0.99 (0.68 - 1.45)
| 1.20 (1.00 - 1.45)
| 1.47 (1.31 - 1.65)
|
HLA-B
| 1.41 (0.63 - 3.12)
| 1.67 (1.37 - 2.03)
| 0.87 (0.56 - 1.36)
| 1.20 (1.04 - 1.38)
| 1.33 (1.18 - 1.51)
|
HLA-C
| 1.16 (1.04 - 1.28)
| 1.44 (1.25 - 1.65)
| 1.04 (0.94 - 1.16)
| 1.01 (0.73 - 1.38)
| 1.28 (1.13 - 1.46)
|
HLA-DRB1
| 1.60 (1.23 - 2.09)
| 1.39 (1.13 - 1.72)
| 1.11 (0.68 - 1.83)
| 1.16 (0.94 - 1.44)
| 1.36 (1.22 - 1.51)
|
HLA-DQB1
| 0.89 (0.37 - 2.14)
| insufficient data
| insufficient data
| 0.99 (0.71 - 1.37)
| 0.95 (0.69 - 1.31)
|
HLA-DPB1
| 2.68 (1.16 - 6.19)
| 1.20 (0.94 - 1.52)
| 1.06 (0.76 - 1.46)
| 0.85 (0.75 - 0.97)
| 0.98 (0.89 - 1.07)
|
Pharmacyclics, Advisor: Consultancy
Fate , Advisor: Advisory Board
Idera, Advisor: Advisory Board
See more of: BMT Tandem "Scientific" Meeting